STAT+: At AACR, Talk Of Chinese Biotech, Oncology’s Comms Issue, And More

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Event context and scope

It represents the final edition of that specific newsletter and references STAT+ subscriber content.

No details beyond the newsletter framing are provided in the source.

This brief derives from STAT’s pop-up newsletter covering the American Association for Cancer Research annual meeting.

Primary development highlighted

Coverage emphasized results for daraxonrasib in first-line pancreatic cancer, and the company also disclosed preliminary findings for a separate investigational molecule, RM-055.

Revolution Medicines presented data that drew strong attendee interest.

Mechanism and novelty reported

Company leadership characterized RM-055 as belonging to a proposed new category described as “catalytic inhibitors.” The reported mechanism is the enzymatic removal of a phosphate group from GTP-bound RAS, effectively switching the RAS protein from its active (“on”) state to an inactive state.

Rationale and resistance implications

Because RM-055 was described as able to inactivate multiple mutant RAS proteins catalytically, the company suggested it could address that resistance mechanism.

The newsletter framed RM-055’s mechanism as potentially important because a documented route to resistance against existing RAS inhibitors involves amplification of mutant RAS, producing large amounts of the active oncoprotein that can overwhelm inhibitors.

Information not provided in source

The source does not report detailed methods, trial design, patient population, quantitative efficacy or safety results for RM-055 or daraxonrasib, regulatory status, or independent corroboration of the mechanistic claims.

Limitations and uncertainty

Assertions about RM-055’s catalytic activity and potential to overcome resistance reflect the company’s presentation and were summarized by STAT; the newsletter does not present confirmatory data or peer-reviewed evidence within the text provided.